Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control-Reference-Cited by-同舟云学术

Switching to the Minimed™ 780G system achieves clinical targets for CGM in adults with type 1 diabetes regardless of previous insulin strategy and baseline glucose control

Published:2022-07-20 Issue:10 Volume:59 Page:1309-1315
ISSN:1432-5233
Container-title:Acta Diabetologica
language:en
Short-container-title:Acta Diabetol

Author:

Lepore Giuseppe^ORCID,Rossini Alessandro,Bellante Rosalia,Corsi Anna,Scaranna Cristiana,Dodesini Alessandro Roberto,Trevisan Roberto

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00592-022-01937-5.pdf

Reference19 articles.

1. Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, Gil-Poch E, Martín-Romo I, Arroyo-Díez FJ (2021) Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 23(9):609–615

2. Collyns OJ, Meier RA, Betts ZL et al (2021) Improved glycemic outcomes with medtronic minimed advanced hybrid closed-loop delivery: results from a randomized crossover trial comparing automated insulin delivery with predictive low glucose suspend in people with type 1 diabetes. Diabetes Care 44(4):969–975

3. Thivolet C, Gaudilliere M, Fimbel SV et al (2021) Hybrid closed Loop improved glucose control compared to sensor-augmented pumps in outpatients with type 1 diabetes in real-life conditions with telehealth monitoring. Acta Diabetol. https://doi.org/10.1007/s00592-021-01820-9

4. Tornese G, Buzzurro F, Carletti C, Faleschini E, Barbi E (2021) Six-month effectiveness of advanced vs standard hybrid closed-loop system in children and adolescents with type 1 diabetes mellitus. Front Endocrinol 12:766314. https://doi.org/10.3389/fendo.2021.766314 (eCollection 2021)

5. Pintaudi B, Gironi I, Nicosia R et al (2022) Minimed Medtronic 780G optimizes glucose control in patients with type 1 diabetes mellitus. Nutr Metab Cardiovasc Dis. https://doi.org/10.1016/j.numecd.2022.03.031

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Excellence in the management of Advanced Hybrid Closed-Loop Systems: Lessons from the Polish cohort;Diabetes Research and Clinical Practice;2024-10

2. Is there a target value for time in tight range for individuals with type 1 diabetes on MDI? Data from masked CGM;Expert Review of Endocrinology & Metabolism;2024-09-05

3. Impact on Glycemia Risk Index and other metrics in type 1 adult patients switching to Advanced Hybrid Closed-Loop systems: a one-year real-life experience;European Journal of Medical Research;2024-07-15

4. A sensor-augmented pump with a predictive low-glucose suspend system could lead to an optimal time in target range during pregnancy in Japanese women with type 1 diabetes;Diabetology International;2024-03-30

5. Advances in Automated Insulin Delivery with the Medtronic 780G: The Australian Experience;Diabetes Technology & Therapeutics;2024-03-01